Bank Julius Baer & Co
FUSN

Bank Julius Baer & Co’s Fusion Pharmaceuticals Inc. Common Shares FUSN Stock Holding History

Bank Julius Baer & Co’s Portfolio FUSN Stock Details FUSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,000
Closed -$8K – 841
2021
Q4 		$8K Hold
2,000
– – ﹤0.01% 795
2021
Q3 		$16K Buy
2,000
+20
+1% +$168 ﹤0.01% 759
2021
Q2 		$16K Buy
+1,980
New +$17K ﹤0.01% 770

Other funds holding FUSN

JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bank Julius Baer & Co's FUSN Position: Q1 2022 in Review

Bank Julius Baer & Co sold out of Fusion Pharmaceuticals Inc. Common Shares (FUSN) in Q1 2022, closing a stake of 2,000 shares — an estimated $8K sold.

Bank Julius Baer & Co first reported a position in FUSN in Q2 2021 and held it in 3 quarters. The position peaked at $16K in Q3 2021. 28 funds tracked by Wall St. Rank hold FUSN as of Q1 2022.

  • Bank Julius Baer & Co reported no remaining Fusion Pharmaceuticals Inc. Common Shares position as of Q1 2022 after selling out during the quarter.
  • Bank Julius Baer & Co sold 2,000 Fusion Pharmaceuticals Inc. Common Shares shares in Q1 2022, an estimated $8K.
  • Bank Julius Baer & Co first reported a position in Fusion Pharmaceuticals Inc. Common Shares in Q2 2021 and held it in 3 quarters.
  • Bank Julius Baer & Co's Fusion Pharmaceuticals Inc. Common Shares position peaked at $16K in Q3 2021.
  • 28 funds tracked by Wall St. Rank held Fusion Pharmaceuticals Inc. Common Shares as of Q1 2022.

Based on Bank Julius Baer & Co's 13F filing for Q1 2022, filed 9 May 2022.